| Year |
Citation |
Score |
| 2023 |
Noelle RJ, Lines JL, Lewis LD, Martell RE, Guillaudeux T, Lee SW, Mahoney KM, Vesely MD, Boyd-Kirkup J, Nambiar DK, Scott AM. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Frontiers in Oncology. 13: 1225081. PMID 37795437 DOI: 10.3389/fonc.2023.1225081 |
0.414 |
|
| 2022 |
Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35594163 DOI: 10.1158/1078-0432.CCR-21-1804 |
0.449 |
|
| 2020 |
Vesely MD. Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. The Yale Journal of Biology and Medicine. 93: 197-206. PMID 32226348 |
0.326 |
|
| 2020 |
Vesely MD, Chen L. Normalization Cancer Immunotherapy for Melanoma. The Journal of Investigative Dermatology. PMID 32092349 DOI: 10.1016/J.Jid.2020.02.005 |
0.526 |
|
| 2019 |
Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, et al. PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine. 11. PMID 31826980 DOI: 10.1126/Scitranslmed.Aax1159 |
0.315 |
|
| 2019 |
Han X, Vesely MD. Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies. International Review of Cell and Molecular Biology. 342: 1-25. PMID 30635089 DOI: 10.1016/Bs.Ircmb.2018.07.003 |
0.457 |
|
| 2014 |
Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515: 577-81. PMID 25428507 DOI: 10.1038/Nature13988 |
0.599 |
|
| 2013 |
Vesely MD, Schreiber RD. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Annals of the New York Academy of Sciences. 1284: 1-5. PMID 23651186 DOI: 10.1111/Nyas.12105 |
0.627 |
|
| 2012 |
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Research. 72: 3987-96. PMID 22869585 DOI: 10.1158/0008-5472.Can-12-1337 |
0.516 |
|
| 2012 |
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 482: 400-4. PMID 22318521 DOI: 10.1038/Nature10755 |
0.597 |
|
| 2011 |
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annual Review of Immunology. 29: 235-71. PMID 21219185 DOI: 10.1146/Annurev-Immunol-031210-101324 |
0.613 |
|
| 2008 |
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 105: 652-6. PMID 18178624 DOI: 10.1073/Pnas.0708594105 |
0.542 |
|
| Show low-probability matches. |